| Title |
Profile of panobinostat and its potential for treatment in solid tumors: an update
|
|---|---|
| Published in |
OncoTargets and therapy, November 2013
|
| DOI | 10.2147/ott.s30773 |
| Pubmed ID | |
| Authors |
Madhurima Anne, Daniel Sammartino, Myra F Barginear, Daniel Budman |
| Abstract |
The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells. Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways. Preclinical data suggests that panobinostat has inhibitory activity at nanomolar concentrations and appears to be the most potent clinically available HDAC inhibitor. Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 3% |
| United States | 1 | 1% |
| Slovakia | 1 | 1% |
| South Africa | 1 | 1% |
| Unknown | 75 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 18% |
| Researcher | 10 | 13% |
| Student > Master | 10 | 13% |
| Student > Doctoral Student | 7 | 9% |
| Student > Bachelor | 7 | 9% |
| Other | 17 | 21% |
| Unknown | 15 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 13% |
| Agricultural and Biological Sciences | 9 | 11% |
| Biochemistry, Genetics and Molecular Biology | 8 | 10% |
| Chemistry | 8 | 10% |
| Other | 6 | 8% |
| Unknown | 13 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2016.
All research outputs
#7,960,052
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#431
of 3,016 outputs
Outputs of similar age
#69,621
of 226,646 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 28 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,646 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.